

- 1.Tito Rodriguez PR, Mehta D, Subhan M, et al. Evolving Horizons in Pediatric Leukemia: Novel Insights, Challenges, and the Journey Ahead. *Cureus*. 2024;16(8):e67480. Published 2024 Aug 22. doi:10.7759/cureus.67480
- 2.Lagunas-Rangel FA, Chávez-Valencia V, Gómez-Guijosa MÁ, Cortes-Penagos C. Acute Myeloid Leukemia-Genetic Alterations and Their Clinical Prognosis. *Int J Hematol Oncol Stem Cell Res*. 2017;11(4):328-339.
- 3.Stubbins, R.J., Karsan, A. Differentiation therapy for myeloid malignancies: beyond cytotoxicity. *Blood Cancer J*. 11, 193 (2021). [Experimental Analysis for double checking the effectiveness of the repurposed drugs.](#)
[Conduct in vitro \(cell lines\) and in vivo \(animal models\) experiments](#)
- 4.Rubnitz JE. How I treat pediatric acute myeloid leukemia. *Blood*. 2012;119(25):5980-5988. doi:10.1182/blood-2012-02-392506
- 5.Vuong JT, Stein-Merlob AF, Cheng RK, Yang EH. Novel Therapeutics for Anthracycline Induced Cardiotoxicity. *Front Cardiovasc Med*. 2022;9:863314. Published 2022 Apr 22. doi:10.3389/fcvm.2022.863314
- 6.Huang L, Li G, Zhang Y, et al. Small-molecule targeting BCAT1-mediated BCAA metabolism inhibits the activation of SHOC2-RAS-ERK to induce apoptosis of Triple-negative breast cancer cells. *J Adv Res*. 2025;75:723-738. doi:10.1016/j.jare.2024.10.021